Why the study?
The efficacy and safety of catheter ablation of ganglionated plexi for vasovagal syncope remained unclear, as did the prognostic comparison between different ganglion-mapping methods.
Does catheter ablation of ganglionated plexi reduce syncope recurrence in patients with refractory vasovagal syncope?
Cohort (n=108)
No
Does catheter ablation of ganglionated plexi reduce syncope recurrence in patients with refractory vasovagal syncope?
Catheter ablation of ganglionated plexi (cardioneuroablation) appears to be a safe and effective treatment for refractory vasovagal syncope, significantly reducing syncope recurrence.
May support cardioneuroablation in refractory vasovagal syncope; leaves open randomized confirmation of efficacy and safety.
Catheter ablation of ganglionated plexi (GPs) performed as cardioneuroablation in the left atrium (LA) has been reported previously as a treatment for vasovagal syncope (VVS). However, the efficacy and safety of catheter ablation in the treatment of VVS remains unclear. The objective of this study is to explore the efficacy and safety of catheter ablation in the treatment of VVS and to compare the different ganglion-mapping methods for prognostic effects. A total of 108 patients with refractory VVS who underwent catheter ablation were retrospectively enrolled. Patients preferred to use high-frequency stimulation (HFS) (n = 66), and anatomic landmark (n = 42) targeting is used when HFS failed to induce a positive reaction. The efficacy of the treatment is evaluated by comparing the location and probability of the intraoperative vagal reflex, the remission rate of postoperative syncope symptoms, and the rate of negative head-up tilt (HUT) results. Adverse events are analyzed, and safety is evaluated. After follow-up for 8 (5, 15) months, both HFS mapping and anatomical ablation can effectively improve the syncope symptoms in VVS patients, and 83.7% of patients no longer experienced syncope (<0.001). Both approaches to catheter ablation in the treatment of VVS effectively inhibit the recurrence of VVS; they are safe and effective. Therefore, catheter ablation can be used as a treatment option for patients with symptomatic VVS.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted a cohort in Vasovagal Syncope (VVS) (n=108). Catheter ablation of left atrial ganglionated plexi vs. High-frequency stimulation (HFS) mapping vs. anatomic landmark ablation was evaluated on Freedom from recurrent syncope (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: